Introduction: Carfilzomib is the second proteasome inhibitor approved worldwide after bortezomib, and the first multiple myeloma treatment drug approved by the FDA in recent years (proteasome inhibitor: protease The main role of the body is to degrade unwanted or damaged proteins in cells, which is achieved by chemical reactions that break peptide bonds). Carfilzomib is a new-generation protease inhibitor administered intravenously that selectively targets the proteasome in hematological tumor cells, avoiding the toxic side effects of inhibiting the constitutive proteasome in non-malignant cells.
Structural formula:
Properties
Summary
Carfilzomib is a proteasome inhibitor. Proteasome can decompose proteins that are damaged or no longer needed, thus playing an important role in cell function and growth.
CRO
